Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Harvard Bioscience (HBIO) Cash from Restructuring (2016)

Harvard Bioscience (HBIO) has disclosed Cash from Restructuring for 6 consecutive years, with -$27000.0 as the latest value for Q3 2016.

Quarterly Cash from Restructuring fell 80.0% to -$27000.0 in Q3 2016 from the year-ago period, while the trailing twelve-month figure was -$27000.0 through Dec 2017, changed 0.0% year-over-year, with the annual reading at -$27000.0 for FY2016, 68.24% up from the prior year.
Cash from Restructuring for Q3 2016 was -$27000.0 at Harvard Bioscience, down from -$6000.0 in the prior quarter.
The five-year high for Cash from Restructuring was $95000.0 in Q3 2013, with the low at -$102000.0 in Q1 2014.
Average Cash from Restructuring over 4 years is -$25272.7, with a median of -$21000.0 recorded in 2013.
The sharpest move saw Cash from Restructuring soared 30.43% in 2014, then plummeted 650.0% in 2015.
Over 4 years, Cash from Restructuring stood at -$97000.0 in 2013, then surged by 97.94% to -$2000.0 in 2014, then plummeted by 200.0% to -$6000.0 in 2015, then plummeted by 350.0% to -$27000.0 in 2016.
According to Business Quant data, Cash from Restructuring over the past three periods came in at -$27000.0, -$6000.0, and -$15000.0 for Q3 2016, Q4 2015, and Q3 2015 respectively.